The University of Chicago Header Logo

Connection

Peter Hulick to Female

This is a "connection" page, showing publications Peter Hulick has written about Female.
Connection Strength

0.441
  1. Patient-Reported Outcomes and Experiences with Population Genetic Testing Offered Through a Primary Care Network. Genet Test Mol Biomarkers. 2021 Feb; 25(2):152-160.
    View in: PubMed
    Score: 0.038
  2. Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice. Fam Cancer. 2014 Dec; 13(4):527-36.
    View in: PubMed
    Score: 0.025
  3. Cytogenetic and array-CGH characterization of a complex de novo rearrangement involving duplication and deletion of 9p and clinical findings in a 4-month-old female. Cytogenet Genome Res. 2009; 126(3):305-12.
    View in: PubMed
    Score: 0.018
  4. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 07 01; 109(7).
    View in: PubMed
    Score: 0.015
  5. Multicenter development and validation of a risk stratification tool for ward patients. Am J Respir Crit Care Med. 2014 Sep 15; 190(6):649-55.
    View in: PubMed
    Score: 0.012
  6. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. Br J Cancer. 2023 06; 128(12):2283-2294.
    View in: PubMed
    Score: 0.011
  7. Association of Reported Candidate Monogenic Genes With Lung Cancer Risk. Clin Lung Cancer. 2023 06; 24(4):313-321.
    View in: PubMed
    Score: 0.011
  8. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. Commun Biol. 2022 10 06; 5(1):1061.
    View in: PubMed
    Score: 0.011
  9. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022 03; 30(3):349-362.
    View in: PubMed
    Score: 0.010
  10. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genet Med. 2021 09; 23(9):1726-1737.
    View in: PubMed
    Score: 0.010
  11. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
    View in: PubMed
    Score: 0.010
  12. Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank. Int J Cancer. 2021 04 01; 148(7):1658-1664.
    View in: PubMed
    Score: 0.009
  13. Mutations of the Transcriptional Corepressor ZMYM2 Cause Syndromic Urinary Tract Malformations. Am J Hum Genet. 2020 10 01; 107(4):727-742.
    View in: PubMed
    Score: 0.009
  14. Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank. Br J Cancer. 2020 10; 123(9):1356-1359.
    View in: PubMed
    Score: 0.009
  15. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020 10; 22(10):1653-1666.
    View in: PubMed
    Score: 0.009
  16. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020 06; 52(6):572-581.
    View in: PubMed
    Score: 0.009
  17. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. Genet Epidemiol. 2020 07; 44(5):442-468.
    View in: PubMed
    Score: 0.009
  18. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet. 2020 01; 52(1):56-73.
    View in: PubMed
    Score: 0.009
  19. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618.
    View in: PubMed
    Score: 0.009
  20. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat. 2019 10; 40(10):1781-1796.
    View in: PubMed
    Score: 0.009
  21. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
    View in: PubMed
    Score: 0.009
  22. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nat Commun. 2019 04 15; 10(1):1741.
    View in: PubMed
    Score: 0.008
  23. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019 04 01; 111(4):350-364.
    View in: PubMed
    Score: 0.008
  24. De novo variants in HK1 associated with neurodevelopmental abnormalities and visual impairment. Eur J Hum Genet. 2019 07; 27(7):1081-1089.
    View in: PubMed
    Score: 0.008
  25. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431.
    View in: PubMed
    Score: 0.008
  26. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res. 2018 09 15; 78(18):5419-5430.
    View in: PubMed
    Score: 0.008
  27. Patient perspectives following pharmacogenomics results disclosure in an integrated health system. Pharmacogenomics. 2018 03; 19(4):321-331.
    View in: PubMed
    Score: 0.008
  28. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017 Dec; 49(12):1767-1778.
    View in: PubMed
    Score: 0.008
  29. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691.
    View in: PubMed
    Score: 0.007
  30. Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet. 2017 04; 25(4):432-438.
    View in: PubMed
    Score: 0.007
  31. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat. 2017 01; 161(1):117-134.
    View in: PubMed
    Score: 0.007
  32. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun. 2016 09 07; 7:12675.
    View in: PubMed
    Score: 0.007
  33. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS One. 2016; 11(7):e0158801.
    View in: PubMed
    Score: 0.007
  34. Patient satisfaction with nipple-sparing mastectomy: A prospective study of patient reported outcomes using the BREAST-Q. J Surg Oncol. 2016 Sep; 114(4):416-22.
    View in: PubMed
    Score: 0.007
  35. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 2016 06 21; 18(1):64.
    View in: PubMed
    Score: 0.007
  36. History repeats itself: the family medication history and pharmacogenomics. Pharmacogenomics. 2016 05; 17(7):669-78.
    View in: PubMed
    Score: 0.007
  37. Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet. 2016 05 05; 98(5):830-842.
    View in: PubMed
    Score: 0.007
  38. Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Hum Mol Genet. 2016 06 01; 25(11):2256-2268.
    View in: PubMed
    Score: 0.007
  39. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet. 2016 Apr; 48(4):374-86.
    View in: PubMed
    Score: 0.007
  40. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15.
    View in: PubMed
    Score: 0.007
  41. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.007
  42. Diagnostic Exome Sequencing Identifies a Novel Gene, EMILIN1, Associated with Autosomal-Dominant Hereditary Connective Tissue Disease. Hum Mutat. 2016 Jan; 37(1):84-97.
    View in: PubMed
    Score: 0.007
  43. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
    View in: PubMed
    Score: 0.006
  44. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Nov; 148(2):397-406.
    View in: PubMed
    Score: 0.006
  45. Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol. 2015 Feb; 22(2):370-6.
    View in: PubMed
    Score: 0.006
  46. Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. Clin J Am Soc Nephrol. 2014 Mar; 9(3):527-35.
    View in: PubMed
    Score: 0.006
  47. Bernard-Soulier syndrome: common ancestry in two African American families with the GP Ib alpha Leu129Pro mutation. Am J Hematol. 2000 Oct; 65(2):141-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.